Smart Immune Receives IRB Approval for Phase I/II Clinical Trial of Proprietary Allogeneic T-Cell Product Smart-101 (ProTcell™) for AML and ALL

Smart Immune SAS, a T cell medicine company utilizing its proprietary ex vivo biomimetic “thymus in a dish” technology to develop allogeneic T-cell progenitors Smart101 for rapid immune reconstitution, announced that the institutional review board (IRB) of the Memorial Sloan Kettering Cancer Center has approved the commencement of the company’s Phase I/II clinical trial.